Table of contents

Electronic pages

• COVID-19 in patients with rheumatic diseases: what is the real mortality risk? (13 July, 2020)

  Claudia Marques, Marcelo M Pinheiro, Edgard Torres Reis Neto, Andrea Tavares Dantas, Francinne Machado Ribeiro, Ana Karla G Melo
• Response to: ‘COVID-19 in patients with rheumatic diseases: what is the real mortality risk?’ by Marques et al

  (13 July, 2020)

  Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Y-T Hsu, Jeffrey A Sparks, Zachary Scott Wallace
• Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’ (31 July, 2020) Free

  Attila Pethoe-Schramm, Jenny Devenport, William Reiss
• Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al

  (31 July, 2020) Free

  Inbal Haya Shafran, Farideh Alasti, Josef S Smolen, Daniel Aletaha
• Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al

  (1 September, 2020) Free

  Chen-Yu Wei, Yung-Heng Lee, James Cheng Chung Wei
• Response to: ‘Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al’ by Wei et al

  (1 September, 2020) Free

  Laure Gossec, Xenofon Baraliakos, Iain McInnes, Andreas Kerschbaumer, Maarten de Wit, Maxime Dougados, Jette Primdahl, Désirée van der Heijde, Josef S Smolen
• Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial—comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al

  (4 August, 2020) Free

  Alessandra Bettiol, Francesca Pregnolato, Savino Sciascia, Giacomo Emmi, Domenico Prisco, Pier Luigi Meroni
• Response to: ‘Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial–comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al’ by Bettiol et al

  (4 August, 2020) Free

  Katerina Chatzidionysiou, Evangelia Samoli, Petros P Sfikakis, Maria G Tektonidou
• Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa? (28 July, 2020)

  Akpabio Akpabio, Richard Oluyinka Akintayo, Utibe Effiong
• Response to: ‘Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?’ by Akpabio et al

  (28 July, 2020)

  Francesco Caso, Antonio del Puente, Nicolò Girolimetto, Marco Tasso, Corrado Caso, Raffaele Scarpa, Luisa Costa
• Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic (11 August, 2020)

  Seow Lin Chuah, Cheng Lay Teh, Sharifah Aishah Wan Mohd Akbar, Yaw Kiet Cheong, Benjamin Sachdev Manjit Singh
• Response to ‘Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic’ by Chuah et al

  (3 September, 2020)

  Alexis Mathian, Zahir Amoura
• Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in rheumatism patients in Wuhan, China’

  (24 July, 2020)

  Xiao-Huan Chen, Chih-Jung Yeh, Han-You Mo, James Cheng Chung Wei
• Response to: ‘Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in patients with rheumatism in Wuhan, China’’ by Chen et al

  (24 July, 2020)

  Jixin Zhong, Cong Ye, Shaozhe Cai, Lingli Dong
• Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia (24 July, 2020)

  Sharifah Aishah Wan, Cheng Lay Teh, Benjamin Sachdev Manjit Singh, Yaw Kiet Cheong, Seow Lin Chuah, Ahmad Tirmizi Jobli
• Response to: ‘Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia’ by Wan et al

  (24 July, 2020)

  Jixin Zhong, Lingli Dong
• Should patients starting biologics be screened for COVID-19? (6 July, 2020)

  Jesus Alberto Cardenas-de la Garza, Rosa I Arvizu-Rivera, Dionicio Angel Galarza-Delgado
• Response to: ‘Should patients starting biologics be screened for COVID-19?’ by Cardenas-de la Garza et al

  (22 July, 2020)

  Robert B M Landewé, Hendrik Schulze-Koops
• Implications of SARS-CoV-2 infection for patients with rheumatic disease (13 August, 2020)

  Changsong Lin, Ziyu Wang, Jie Li, Xinyi Xia, Yun Liu, Qianghu Wang
• Response to: ‘Implications of SARS-CoV-2 infection for patients with rheumatic disease’ by Lin et al

  (7 September, 2020)

  Alexis Mathian, Zahir Amoura
• Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest? (9 July, 2020)

  Pedro Santos-Moreno, Diana Buitrago-Garcia, Laura Villarreal, Anggie Aza, Michael Cabrera, Wilberto Rivero, Adriana Rojas-Villarraga
• Response to: ‘Emergency arising from patients’ fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?’ by Santos-Moreno et al

  (9 July, 2020)

  Jean W Liew, Elizabeth R Graef, Jeffrey A Sparks, Alfred Hyoungju Kim
• Correction: B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus

  (12 July, 2022) Free